Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.26 EPS on February, 26.They anticipate $0.01 EPS change or 3.70% from last quarter’s $-0.27 EPS. After having $-0.50 EPS previously, FibroGen, Inc.’s analysts see -48.00% EPS growth. The stock decreased 1.50% or $0.88 during the last trading session, reaching $57.62. About 423,789 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 13.72% since February 20, 2018 and is downtrending. It has underperformed by 13.72% the S&P500. Some Historical FGEN News: 09/05/2018 – FibroGen 1Q Rev $31.9M; 06/04/2018 – HK Bourse: Announcement From Pacific Andes International Holdings Ltd; 31/05/2018 – ASTELLAS PHARMA INC – FOURTH JAPAN PHASE 3 STUDY FOR ROXADUSTAT MET ITS PRIMARY ENDPOINT; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic; 31/05/2018 – ASTELLAS PHARMA INC – SAFETY PROFILE OF ROXADUSTAT WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUS STUDIES BOTH IN DIALYSIS AND NON-DIALYSIS PATIENTS; 21/05/2018 – FIBROGEN: PAMREVLUMAB SLOWED IPF DISEASE PROGRESSION IN STUDY; 14/05/2018 – FibroGen Closes Above 200-Day Moving Average: Technicals; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom; 12/04/2018 – ARGENTINA IS SAID TO PROBE TRADES OF ANDES FOR INSIDER TRADING; 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDY
Seaworld Entertainment Inc (SEAS) investors sentiment increased to 1.05 in Q3 2018. It’s up 0.42, from 0.63 in 2018Q2. The ratio improved, as 78 hedge funds opened new or increased stock positions, while 74 cut down and sold their equity positions in Seaworld Entertainment Inc. The hedge funds in our database now own: 52.92 million shares, down from 58.00 million shares in 2018Q2. Also, the number of hedge funds holding Seaworld Entertainment Inc in top ten stock positions was flat from 3 to 3 for the same number . Sold All: 23 Reduced: 51 Increased: 36 New Position: 42.
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.90 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
More recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Seekingalpha.com which released: “Piper likes ChemoCentryx in premarket analyst action – Seeking Alpha” on February 11, 2019. Also Nasdaq.com published the news titled: “Implied IYY Analyst Target Price: $152 – Nasdaq” on February 07, 2019. Nasdaq.com‘s news article titled: “First Week of FGEN February 15th Options Trading – Nasdaq” with publication date: January 07, 2019 was also an interesting one.
Dsam Partners (London) Ltd holds 4.24% of its portfolio in SeaWorld Entertainment, Inc. for 920,582 shares. Managed Asset Portfolios Llc owns 373,898 shares or 3.11% of their US portfolio. Moreover, Van Berkom & Associates Inc. has 1.91% invested in the company for 2.14 million shares. The California-based Phocas Financial Corp. has invested 1.3% in the stock. Emerald Advisers Inc Pa, a Pennsylvania-based fund reported 1.07 million shares.
SeaWorld Entertainment, Inc., together with its subsidiaries, operates as a theme park and entertainment firm in the United States. The company has market cap of $2.28 billion. The firm operates marine-life theme park under the SeaWorld brand name in San Diego, Orlando, and San Antonio; Busch Gardens theme parks, which are family-oriented destinations with foreign geographic settings in Tampa and Williamsburg; and water parks under the Aquatica brand in Orlando, San Antonio, and San Diego. It has a 64.68 P/E ratio. It also operates the Adventure Island name in Tampa; Water Country USA name in Williamsburg; Discovery Cove marine life theme park in Orlando; and Sesame Place, a seasonal park in Langhorne.
The stock increased 3.59% or $0.9 during the last trading session, reaching $26. About 1.60M shares traded or 2.16% up from the average. SeaWorld Entertainment, Inc. (SEAS) has risen 114.90% since February 20, 2018 and is uptrending. It has outperformed by 114.90% the S&P500. Some Historical SEAS News: 30/04/2018 – Daily Mail: Thomas Cook gives SeaWorld three-month ultimatum to fix animal welfare concerns over treatment of killer whales or; 17/05/2018 – SeaWorld 32.9% Owned by Hedge Funds; Hill Path Capital LP Leads; 11/05/2018 – SeaWorld Makes a Splash — Barrons.com; 08/05/2018 – SeaWorld Entertainment 1Q Attendance Increased 14.9%; 08/05/2018 – SEAWORLD 1Q LOSS/SHR 73C; 12/04/2018 – SEAWORLD ENTERTAINMENT RECEIVED A WRITTEN WELLS NOTICE; 08/05/2018 – SeaWorld Entertainment 1Q Loss $62.8M; 12/04/2018 – SeaWorld: No Current Employee Has Received an SEC Wells Notice; 12/04/2018 – SeaWorld Got Wells Notice From SEC Staff on April; 15/05/2018 – Armistice Capital Buys New 2.3% Position in SeaWorld
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.